Statin Use in Patients With Advanced Prostate Cancer in the TITAN and SPARTAN Trials.

ABSTRACT:

Importance

The impact of statins on overall survival (OS) in patients with prostate cancer treated using intensified therapy with apalutamide is not fully understood.

Objective

To determine whether statin exposure was associated with OS and grade 3 or greater cardiac adverse events (AEs) in patients treated with apalutamide.

Design, setting, and participants

This cohort study used individual patient data from 2 multicenter phase 3 randomized clinical trials, SPARTAN (October 14, 2013, to December 15, 2016) and TITAN (December 15, 2015, to July 25, 2017). The final analysis was done on May 21, 2025. TITAN and SPARTAN randomized patients to receive androgen deprivation therapy with or without apalutamide in metastatic hormone-sensitive prostate cancer (TITAN) and nonmet

SUBMITTER: Roy S 

PROVIDER: S-EPMC12368675 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature